Bioverativ

Bioverativ was an American biotechnology company created from Biogen's hemophilia business. Its principal focus was the discovery, development, and commercialization of therapies for people with hemophilia and related blood disorders. The company inherited two marketed factor-replacement products from Biogen: Eloctate, an extended-half-life factor VIII therapy for hemophilia A, and Alprolix, an extended-half-life factor IX therapy for hemophilia B. These products formed the commercial foundation of the business and were marketed across the United States, the European Union, Japan, Canada, and Australia. Biogen announced in May 2016 that it intended to separate its hemophilia portfolio into an independent publicly traded company. The name Bioverativ was announced later that year and was designed to retain a connection to Biogen while establishing a distinct corporate identity. The separation was completed in early 2017. Biogen shareholders received Bioverativ shares through a special distribution, and Bioverativ began trading on the Nasdaq under the symbol BIVV on January 12, 2017. As an independent company, Bioverativ combined an established hemophilia franchise with a pipeline and business-development strategy centered on rare blood diseases. In May 2017, it agreed to acquire True North Therapeutics for $825 million. The transaction added TNT009, an investigational treatment associated with cold agglutinin disease, and expanded Bioverativ beyond factor-replacement products into additional hematology indications. Bioverativ remained independent for only a short period. In January 2018, Sanofi announced an agreement to acquire the company, and the transaction was completed on March 8, 2018. Bioverativ consequently ceased to operate as an independent publicly traded company and became part of Sanofi's business. Its historical identity is therefore best understood as a focused rare-disease biotechnology company established through a corporate spin-off, built around Eloctate and Alprolix, expanded through the True North acquisition, and ultimately absorbed by a larger pharmaceutical group. The company operated in a competitive hemophilia market that included businesses associated with Baxalta, Pfizer, and Novo Nordisk. Its differentiation rested primarily on extended-half-life factor products and specialized expertise in inherited bleeding disorders. Later reporting also connected Bioverativ and Sanofi with litigation concerning alleged insider trading around the Sanofi acquisition; the matter was settled in 2023.

Bioverativ originated in Biogen's decision to separate its hemophilia business into an independent company. In May 2016, Biogen announced that Eloctate and Alprolix would be transferred into a new publicly traded entity. The planned separation reflected Biogen's effort to create a more focused company around hemophilia while allowing the parent company to concentrate on its remaining biotechnology businesses. In August 2016, Biogen announced the name Bioverativ. The name preserved an association with Biogen while signaling that the new organization would have its own corporate identity. The U.S. Securities and Exchange Commission approved the company's registration statement on December 22, 2016. The separation was scheduled for early 2017, with eligible Biogen shareholders receiving Bioverativ shares through a special distribution based on their Biogen holdings. Bioverativ began trading on Nasdaq on January 12, 2017, under the ticker BIVV. The new company inherited two commercially established products. Eloctate served people with hemophilia A, while Alprolix served people with hemophilia B. Both were extended-half-life factor products designed to support less frequent dosing than some conventional replacement regimens. They were sold in several major pharmaceutical markets, including the United States, the European Union, Japan, Canada, and Australia. The products gave Bioverativ an established revenue base and a recognizable position in the global hemophilia-treatment market. Bioverativ also sought to expand beyond its initial product portfolio. In May 2017, it announced an agreement to acquire True North Therapeutics for $825 million. True North brought TNT009, an investigational treatment connected with cold agglutinin disease, into Bioverativ's development portfolio. The deal represented an attempt to use the company's expertise in rare blood disorders as a platform for broader hematology growth rather than relying exclusively on existing factor-replacement products. The independent company's life was brief. In January 2018, Sanofi announced that it would acquire Bioverativ for $11.6 billion. The transaction was completed on March 8, 2018. Following completion, Bioverativ was no longer an independent listed company and operated within Sanofi's pharmaceutical organization. Bioverativ competed in a market that included Baxalta, Pfizer, and Novo Nordisk. Its historical competitive identity was based on specialized hemophilia knowledge, an established portfolio of extended-half-life factor therapies, and efforts to build a wider rare-blood-disease pipeline. The company later became involved in litigation related to allegations that members of its board helped a hedge-fund manager profit from advance knowledge of the Sanofi transaction. Bioverativ and Sanofi settled that matter in 2023 for a reported $84 million. Because the brand was absorbed into Sanofi in 2018, Bioverativ is now principally a historical corporate identity rather than an independent operating company.

• 2023

  Insider-trading-related case settled

  [1]Bioverativen.wikipedia.org

  Bioverativ and Sanofi settled litigation concerning alleged profits made from advance knowledge of the Sanofi acquisition.

• 2018

  Sanofi acquisition completed

  [1]Bioverativen.wikipedia.org

  Sanofi completed its acquisition of Bioverativ on March 8, ending Bioverativ's existence as an independent listed company.

• 2017

  Independent trading begins

  [1]Bioverativen.wikipedia.org

  Bioverativ began trading on Nasdaq under the symbol BIVV on January 12 after shares were distributed to eligible Biogen investors.

• 2017

  True North Therapeutics acquisition announced

  [1]Bioverativen.wikipedia.org

  Bioverativ agreed to acquire True North Therapeutics for $825 million, adding the investigational asset TNT009 to its blood-disorder pipeline.

• 2016

  Biogen announces the hemophilia-business spin-off

  [1]Bioverativen.wikipedia.org

  Biogen announced that Eloctate and Alprolix would be placed into a separate publicly traded company focused on hemophilia and related blood disorders.

• 2016

  Bioverativ name selected

  [1]Bioverativen.wikipedia.org

  Biogen announced Bioverativ as the name of the planned spin-off, retaining a visible connection to Biogen's heritage.

• 2016

  Registration statement approved

  [1]Bioverativen.wikipedia.org

  The Securities and Exchange Commission approved Bioverativ's registration statement on December 22, clearing an important regulatory step for the separation.

A specialized rare-disease biotechnology company focused on hemophilia, factor-replacement therapies, and the development of treatments for other serious blood disorders.

• Hemophilia A therapy

  Eloctate

  Eloctate was one of Bioverativ's two principal inherited products from Biogen. It is an extended-half-life factor VIII replacement therapy used in the treatment and prevention of bleeding in people with hemophilia A. The product formed a central part of Bioverativ's commercial identity and was marketed in multiple international regions, including the United States, the European Union, Japan, Canada, and Australia.

• Hemophilia B therapy

  Alprolix

  Alprolix was Bioverativ's extended-half-life factor IX replacement therapy for hemophilia B. Alongside Eloctate, it was transferred from Biogen into the spin-off and provided Bioverativ with an established commercial foothold in inherited bleeding disorders. Its international marketing footprint included the United States, the European Union, Japan, Canada, and Australia.

• Investigational hematology therapy

  TNT009

  TNT009 was an investigational therapy added to Bioverativ's pipeline through its 2017 acquisition of True North Therapeutics. The asset was associated with development efforts for cold agglutinin disease and represented Bioverativ's attempt to broaden its research portfolio beyond hemophilia factor replacement.

• 2023

  Settlement of insider-trading-related litigation

  Bioverativ and Sanofi settled a case alleging that Bioverativ's board assisted a hedge-fund manager in profiting from nonpublic information about Sanofi's planned acquisition of Bioverativ. The reported settlement amount was $84 million.

  Source

Read more

• 2018

  Accept Sanofi acquisitionM&A

  Background

  Sanofi pursued Bioverativ as a way to obtain a focused hemophilia business and expand its presence in rare blood disorders.

  Action taken

  Sanofi announced a $11.6 billion acquisition and completed the transaction on March 8, 2018.

  Aftermath

  Bioverativ ceased to be an independent Nasdaq-listed company and became part of Sanofi.

  Acquisition value. $11.6 billion (2018 announcement and completion)

  Source

• 2017

  Acquire True North TherapeuticsM&A

  Background

  Bioverativ sought to strengthen its pipeline and extend its rare-blood-disorder focus beyond its two marketed hemophilia products.

  Action taken

  Bioverativ announced an agreement to acquire True North Therapeutics for $825 million, including the investigational asset TNT009.

  Aftermath

  The acquisition broadened Bioverativ's development portfolio to include an opportunity associated with cold agglutinin disease.

  Acquisition value. $825 million (2017 announcement)

  Source

• 2016

  Separate the hemophilia business from BiogenStrategy

  Background

  Biogen decided to create an independent company around Eloctate and Alprolix, its hemophilia-focused commercial assets.

  Action taken

  Biogen prepared a public-company spin-off, selected the Bioverativ name, and distributed shares to eligible Biogen investors.

  Aftermath

  Bioverativ began trading independently in January 2017 and became a specialized publicly traded hemophilia company.

  Source

1. 1Bioverativen.wikipedia.org